Menu

Coriell Institute CEO Dies

Michael Christman oversaw the organization’s well-known biobank and pioneered a personalized medicine initiative.

Jan 4, 2018
Kerry Grens

CORIELL INSTITUTE FOR MEDICAL RESEARCHThe president and CEO of the Coriell Institute for Medical Research in New Jersey, Michael Christman, died unexpectedly last month (December 25). He was 58.

Christman had founded the Genetics and Genomics department at Boston University in 2001. At Coriell, he had managed a famous biobank that included a diverse collection of induced pluripotent stem cells and launched a personalized medicine project that has recruited thousands of volunteers to share their health and genetic information and receive information about disease risks in return.

“The importance of Dr. Christman’s impact not only on the Coriell Institute, but personalized medicine as a whole cannot be overstated,” Robert Kiep, III, the chairman of the Coriell Institute Board of Trustees, says in a statement. “It was his initiative that got this project off the ground and his guidance that turned it into the unequivocal success that it is today. His death is a terrible loss for us all.”

A North Carolina native, Christman earned a chemistry degree from the University of North Carolina, then a PhD in biochemistry from the University of California, Berkeley. He held a faculty position at the University of California, San Francisco, before his time at Boston University.

According to an obituary on philly.com, Christman’s work at Boston University included a genetics project using data from the Framingham Heart Study to hunt for variants related to obesity.

In 2007, Christman joined the Coriell Institute and sprearheaded the personalized medicine initiative. “The goal is to see information obtained from the human genome project [that will] start to influence clinical medical practice,” Christman told The Scientist in 2008. “We want to build a bridge from information that we now have about genomics from scientific research, and have that information actually change medical decision-making by doctors.”

At the time of his death, Christman and his two children had been visiting family in North Carolina for the holidays. “He went to bed about 9 p.m. on Christmas Eve. He wasn’t feeling well,” his father, Russell Christman, tells philly.com. “We guess it was his heart.”

In addition to his father, Christman is survived by his 16-year-old twins, Max and Emma, two brothers, his stepmother, and his ex-wife.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.